Stay updated on Pralsetinib in RET+ Cancer Clinical Trial

Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0 on the page.
    Difference
    0.0%
    Check dated 2026-03-20T22:24:38.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-06T17:54:33.000Z thumbnail image
  4. Check
    22 days ago
    No Change Detected
  5. Check
    36 days ago
    Change Detected
    Summary
    Revision: v3.4.2 is shown on the page, replacing v3.4.1. The content related to the study remains unchanged.
    Difference
    0.0%
    Check dated 2026-02-13T12:48:53.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1; no user-visible changes to page content were detected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-06T09:14:55.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    Added glossary toggle options (Show glossary / Hide glossary) and minor metadata label changes (capitalization and revision/version update from v3.3.4 to v3.4.0) that do not affect the study's core content.
    Difference
    0.2%
    Check dated 2026-01-22T17:48:28.000Z thumbnail image
  8. Check
    65 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; no study data, eligibility criteria, or locations appear to be affected.
    Difference
    0.0%
    Check dated 2026-01-15T10:45:06.000Z thumbnail image

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.